ArticleFrontiers in genetics2022
Bioinformatics searching of diagnostic markers and immune infiltration in polycystic ovary syndrome.
Article in Frontiers in genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Decoding the senescent endothelial landscape in ischemic stroke through single-cell and bulk RNA sequencing.Functional & integrative genomics · 2026Article
- Decoding the significance of TERT gene in Polycystic Ovary Syndrome: From molecular mechanisms to emerging diagnostic and therapeutic strategies.Journal of ovarian research · 2026Review
- Article
- Next-generation Approaches in Targeting Polycystic Ovarian Syndrome: Innovative Strategies.Current medicinal chemistry · 2026Review
- Integrative multi-omics analysis of druggable genes for therapeutic target identification in polycystic ovary syndrome.Journal of ovarian research · 2025Article
- Transcriptomic Profiling Reveals Potential Genes Involved in the Immune Landscape of Polycystic Ovary Syndrome: An Exploratory Study.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Comparing survival outcomes between surgical and non-surgical treatments in patients with early-onset endometrial cancer and developing a nomogram to predict survival: a study based on Eastern and Western data sets.World journal of surgical oncology · 2025Article
- Region-specific roles of oviductal motile cilia in oocyte/embryo transport and fertility†.Biology of reproduction · 2025Article
- Identification of mitophagy-related biomarkers and immune infiltration in polycystic ovarian syndrome by bioinformatic study.Heliyon · 2025Article
- Development of machine learning models for diagnostic biomarker identification and immune cell infiltration analysis in PCOS.Journal of ovarian research · 2025Article
- Integrated Transcriptome Analysis of lncRNA, miRNA, and mRNA Reveals key Regulatory Modules for Polycystic Ovary Syndrome.Phenomics (Cham, Switzerland) · 2024Article
- Identification and validation of senescence-related genes in polycystic ovary syndrome.Journal of ovarian research · 2024Article
- Homeobox regulator Wilms Tumour 1 is displaced by androgen receptor at cis-regulatory elements in the endometrium of PCOS patients.Frontiers in endocrinology · 2024Article
- Polycystic Ovary Syndrome: Pathophysiology and Controversies in Diagnosis.Diagnostics (Basel, Switzerland) · 2023Review
- N6-methyladenosine regulator-mediated methylation modification patterns and immune infiltration characterization in Polycystic Ovary Syndrome (PCOS).Journal of ovarian research · 2023Article
- A novel model based on necroptosis to assess progression for polycystic ovary syndrome and identification of potential therapeutic drugs.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrine diseases in reproductive-aged women, and it affects numerous women worldwide. This study aimed to identify potential diagnostic markers and explore the infiltration of immune cells in PCOS, contributing to the development of potential therapeutic drugs for this disease. We identified five key genes: CBLN1 (AUC = 0.924), DNAH5 (AUC = 0.867), HMOX1 (AUC = 0.971), SLC26A8 (AUC = 0,933), and LOC100507250 (AUC = 0.848) as diagnostic markers of PCOS. Compared with paired normal group, naïve B cells, gamma delta T cells, resting CD4 memory T cells, and activated CD4 memory T cells were significantly decreased in PCOS while M2 macrophages were significantly increased. Significant correlations were presented between the five key genes and the components of immune infiltrate. The results of CMap suggest that four drugs, ISOX, apicidin, scriptaid, and NSC-94258, have the potential to reverse PCOS. The present study helps provide novel insights for the prevention and treatment of PCOS, and immune cell infiltration plays a role that cannot be ignored in the occurrence and progression of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.